Farver D K, Hansen L A
Department of Clinical Pharmacy, South Dakota State University College of Pharmacy, Yankton.
Ann Pharmacother. 1994 Dec;28(12):1344-6. doi: 10.1177/106002809402801203.
To report a case of ticlopidine-induced neutropenia occurring 18 days after discontinuation of the drug.
A 68-year-old woman was placed on ticlopidine after a transient ischemic attack. Ten days later the drug was discontinued because the patient developed a rash. Eighteen days later she developed pneumonia and neutropenia, which were believed to be induced by ticlopidine.
Drug-induced neutropenia is serious and at times life-threatening. Ticlopidine-induced neutropenia has been described in patients receiving the medication. We report neutropenia occurring 18 days after discontinuation of ticlopidine.
Indications for prescribing ticlopidine must be closely followed. Complete blood cell count monitoring is imperative while the patient is receiving the medication. This case suggests that the duration of monitoring after the discontinuation of ticlopidine may need to be longer than the 14 days recommended by the manufacturer.
报告1例在停用噻氯匹定18天后发生的噻氯匹定诱导的中性粒细胞减少症病例。
一名68岁女性在短暂性脑缺血发作后开始服用噻氯匹定。10天后，由于患者出现皮疹，停用了该药物。18天后，她患上肺炎并出现中性粒细胞减少症，据信这是由噻氯匹定引起的。
药物性中性粒细胞减少症很严重，有时会危及生命。接受该药物治疗的患者中曾有噻氯匹定诱导的中性粒细胞减少症的报道。我们报告了在停用噻氯匹定18天后发生的中性粒细胞减少症。
必须严格遵循噻氯匹定的处方指征。患者接受药物治疗期间必须进行全血细胞计数监测。该病例表明，停用噻氯匹定后的监测时间可能需要比制造商推荐的14天更长。
